CAD106 Uses, Dosage, Side Effects and more
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
CAD106 can block the formation of beta-amyloid plaques in the brain. Since the formation of such plaques is considered a hallmark of the disease, CAD106 may offer the potential to advance the treatment of Alzheimer's disease.
| Trade Name | CAD106 |
| Generic | CAD106 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in alzheimer's disease.
How CAD106 works
CAD106 is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients. CAD106 consists of two components, the Immunodrug carrier Qb coupled with a fragment of the beta-amyloid-protein. In animal studies it has been shown that treatment with CAD106 can block the formation of beta-amyloid plaques in the brain.
